Replies to post #39017 on Biotech Values

[DewDiligence]

ENTA gets a little exposure in (tomorrow’s) WSJ story on ABBV:

http://www.wsj.com/articles/abbvie-pins-hopes-on-hepatitis-c-treatment-1418855059

AbbVie’s product stems partly from a 2006 partnership with Enanta Pharmaceuticals of Watertown, Mass. [#msg-15492225]. The collaboration produced ABT-450, or paritaprevir, which is known as a protease inhibitor and works with other drugs in the regimen to block replication of the hepatitis C virus.

Abbott Labs and now AbbVie have paid $160 million to Enanta in the form of an upfront fee and subsequent research milestone payments, according to Enanta. And AbbVie will pay more if the hepatitis C regimen is approved.

Specifically, ABBV will pay ENTA a $75M milestone for FDA approval, another $75M milestone for EMA approval (expected in early 2015), and a 4-6% tiered royalty on worldwide gross sales of the 3-DAA regimen.